Advances in Ophthalmic Optogenetics: Approaches and Applications
Open accessThe DOI matches its Crossref record; 96 of the 99 references it cites were found in a registry or an index.
Abstract
Recent advances in optogenetics hold promise for vision restoration in degenerative eye diseases. Optogenetics refers to techniques that use light to control the cellular activity of targeted cells. Although optogenetics is a relatively new technology, multiple therapeutic options are already being explored in pre-clinical and phase I/II clinical trials with the aim of developing novel, safe, and effective treatments for major blinding eye diseases, such as glaucoma and retinitis pigmentosa. Optogenetic approaches to visual restoration are primarily aimed at replacing lost or dysfunctional photoreceptors by inserting light-sensitive proteins into downstream retinal neurons that have no intrinsic light sensitivity. Such approaches are attractive because they are agnostic to the genetic causes of retinal degeneration, which raises hopes that all forms of retinal dystrophic and degenerative diseases could become treatable. Optogenetic strategies can also have a far-reaching impact on translational research by serving as important tools to study the pathogenesis of retinal degeneration and to identify clinically relevant therapeutic targets. For example, the CRY-CIBN optogenetic system has been recently applied to animal models of glaucoma, suggesting a potential role of OCRL in the regulation of intraocular pressure in trabecular meshwork. As optogenetic strategies are being intensely investigated, it appears crucial to consider the opportunities and challenges such therapies may offer. Here, we review the more recent promising optogenetic molecules, vectors, and applications of optogenetics for the treatment of retinal degeneration and glaucoma. We also summarize the preliminary results of ongoing clinical trials for visual restoration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, optogenetics still require optimization to allow for complex visual processing and to increase the sensitivity of the proteins that are currently used.10,15”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Steinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189
(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Neurodegenerative Disorders: Parkinson's Disease and Huntington's Disease
Hague, S., Klaffke, S., & Bandmann, O. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860948961_0007 · Cited by 2,767
Gordon, M. O. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.714 · Cited by 2,626
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Independent optical excitation of distinct neural populations
Klapoetke, N. C., Murata, Y., Kim, S. S., Pulver, S. R., Birdsey-Benson, A., Cho, Y. K., Morimoto, T. K., Chuong, A. S., Carpenter, E. J., Tian, Z., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2836 · Cited by 2,344 · cited 2×
“Natural and engineered variants of ChR, such as ChrimsonR and ChronosFP, have different kinetics and sensitivities to light and are also used in optogenetic therapies [35].”
BackgroundWeinreb, R. N., & Khaw, P. T. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16257-0 · Cited by 2,222
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Clinical trials for gene therapy to treat LCA have demonstrated the safety and efficacy of subretinal delivery of transgenes to the retina via an AAV2 vector [92,93].”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Clinical trials for gene therapy to treat LCA have demonstrated the safety and efficacy of subretinal delivery of transgenes to the retina via an AAV2 vector [92,93].”
BackgroundPAS Domains: Internal Sensors of Oxygen, Redox Potential, and Light
Taylor, B. L., & Zhulin, I. B. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.2.479-506.1999 · Cited by 1,632
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 2×
“Furthermore, the maximum capacity of AAVs to accommodate genomic information is approximately 4.8 kb, which prevents their use for the delivery of large genes, such as USH2A [53].”
BackgroundInfluentialOptogenetics: 10 years of microbial opsins in neuroscience
Deisseroth, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4091 · Cited by 1,283
Rapid blue-light–mediated induction of protein interactions in living cells
Kennedy, M. J., Hughes, R. M., Peteya, L. A., Schwartz, J. W., Ehlers, M. D., & Tucker, C. L. (2010) · Nature Methods · doi:10.1038/nmeth.1524 · Cited by 1,120
Next-Generation Optical Technologies for Illuminating Genetically Targeted Brain Circuits
Deisseroth, K., Feng, G., Majewska, A. K., Miesenböck, G., Ting, A., & Schnitzer, M. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3863-06.2006 · Cited by 812
Posch, C., Matolin, D., & Wohlgenannt, R. (2011) · IEEE Journal of Solid-State Circuits · doi:10.1109/jssc.2010.2085952 · Cited by 793
Bi, A., Cui, J., Ma, Y.-P., Olshevskaya, E., Pu, M., Dizhoor, A. M., & Pan, Z.-H. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.026 · Cited by 771
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“7m8 capsid variant that features a peptide on its heparin binding site [8,87].”
BackgroundArabidopsis NPH1: A Protein Kinase with a Putative Redox-Sensing Domain
Huala, E., Oeller, P. W., Liscum, E., Han, I.-S., Larsen, E., & Briggs, W. R. (1997) · Science · doi:10.1126/science.278.5346.2120 · Cited by 709
Partial recovery of visual function in a blind patient after optogenetic therapy
Sahel, J.-A., Boulanger-Scemama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J. N., Esposti, S. D., Delaux, A., de Saint Aubert, J.-B., de Montleau, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01351-4 · Cited by 700
Liew, G., Michaelides, M., & Bunce, C. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004015 · Cited by 663
Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa
Busskamp, V., Duebel, J., Balya, D., Fradot, M., Viney, T. J., Siegert, S., Groner, A. C., Cabuy, E., Forster, V., Seeliger, M., et al. (2010) · Science · doi:10.1126/science.1190897 · Cited by 642
Retinitis Pigmentosa: Genes and Disease Mechanisms
Parmeggiani, F., S. Sorrentino, F., Ponzin, D., Barbaro, V., Ferrari, S., & Di Iorio, E. (2011) · Current Genomics · doi:10.2174/138920211795860107 · Cited by 627
Lagali, P. S., Balya, D., Awatramani, G. B., Münch, T. A., Kim, D. S., Busskamp, V., Cepko, C. L., & Roska, B. (2008) · Nature Neuroscience · doi:10.1038/nn.2117 · Cited by 582
Salomon, M., Christie, J. M., Knieb, E., Lempert, U., & Briggs, W. R. (2000) · Biochemistry · doi:10.1021/bi000585+ · Cited by 564
Maximum permissible exposures for ocular safety (ANSI 2000), with emphasis on ophthalmic devices
Delori, F. C., Webb, R. H., & Sliney, D. H. (2007) · Journal of the Optical Society of America A · doi:10.1364/josaa.24.001250 · Cited by 480
Retinal remodeling triggered by photoreceptor degenerations
Jones, B. W., Watt, C. B., Frederick, J. M., Baehr, W., Chen, C., Levine, E. M., Milam, A. H., Lavail, M. M., & Marc, R. E. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10703 · Cited by 476
Perspective on Genes and Mutations Causing Retinitis Pigmentosa
Daiger, S. P. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.2.151 · Cited by 467
Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
Hanany, M., Rivolta, C., & Sharon, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913179117 · Cited by 408
Photochemical Damage of the Retina
Wu, J., Seregard, S., & Algvere, P. V. (2006) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2006.06.009 · Cited by 396
Wiggs, J. L., & Pasquale, L. R. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx184 · Cited by 373
Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368
The Cryptochrome Blue Light Receptors
Yu, X., Liu, H., Klejnot, J., & Lin, C. (2010) · The Arabidopsis Book · doi:10.1199/tab.0135 · Cited by 338
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies
Sohocki, M. M., Daiger, S. P., Bowne, S. J., Rodriquez, J. A., Northrup, H., Heckenlively, J. R., Birch, D. G., Mintz-Hittner, H., Ruiz, R. S., Lewis, R. A., et al. (2001) · Human Mutation · doi:10.1002/1098-1004(2001)17:1<42::aid-humu5>3.0.co;2-k · Cited by 329
Youssef, P. N., Sheibani, N., & Albert, D. M. (2011) · Eye · doi:10.1038/eye.2010.149 · Cited by 318
Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin
Lin, B., Koizumi, A., Tanaka, N., Panda, S., & Masland, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806114105 · Cited by 302
Histologic analysis of photochemical lesions produced in rhesus retina by short-wave-length light.
Ham, W. T., Ruffolo, J. J., Mueller, H. A., Clarke, A., & Moon, M. (1978) · PubMed · Cited by 292
Function, structure and mechanism of bacterial photosensory LOV proteins
Herrou, J., & Crosson, S. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2622 · Cited by 278
Doroudchi, M. M., Greenberg, K. P., Liu, J., Silka, K. A., Boyden, E. S., Lockridge, J. A., Arman, A. C., Janani, R., Boye, S. E., Boye, S. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.69 · Cited by 277
(2013) · Health Physics · doi:10.1097/hp.0b013e3182983fd4 · Cited by 252
Photoreceptor cell death and rescue in retinal detachment and degenerations
Murakami, Y., Notomi, S., Hisatomi, T., Nakazawa, T., Ishibashi, T., Miller, J. W., & Vavvas, D. G. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.08.001 · Cited by 247
Optogenetic therapy for retinitis pigmentosa
Busskamp, V, Picaud, S., Sahel, J. A., & Roska, B. (2012) · Gene Therapy · doi:10.1038/gt.2011.155 · Cited by 235
Mazzoni, F., Novelli, E., & Strettoi, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4968-08.2008 · Cited by 235
Molday, R. S., & Moritz, O. L. (2015) · Journal of Cell Science · doi:10.1242/jcs.175687 · Cited by 235
Klimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210 · cited 1×
“Furthermore, the optogenetic modules themselves will improve because of developments in their sensitivity as artificial photoreceptors or as sensors responsive to a wide range of wavelengths, including near-infrared wavelengths [56].”
BackgroundRetinal prosthetic strategy with the capacity to restore normal vision
Nirenberg, S., & Pandarinath, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207035109 · Cited by 207
Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
Wilson, J. M., & Flotte, T. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.182 · Cited by 203 · cited 1×
“Although systemic delivery of AAV vectors in gene therapy has proven to be more challenging, AAV vectors in optogenetic applications have the advantage of offering flexibility in the choice of the delivery route [50].”
BackgroundHeath Jeffery, R. C., Mukhtar, S. A., McAllister, I. L., Morgan, W. H., Mackey, D. A., & Chen, F. K. (2021) · Ophthalmic Genetics · doi:10.1080/13816810.2021.1913610 · Cited by 198
Macé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.-A., Picaud, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.154 · Cited by 197
Mechanisms of Photoreceptor Death in Retinitis Pigmentosa
Newton, F., & Megaw, R. (2020) · Genes · doi:10.3390/genes11101120 · Cited by 195
Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
Xue, K., Jolly, J. K., Barnard, A. R., Rudenko, A., Salvetti, A. P., Patrício, M. I., Edwards, T. L., Groppe, M., Orlans, H. O., Tolmachova, T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0185-5 · Cited by 185
Restoration of vision with ectopic expression of human rod opsin
Cehajic-Kapetanovic, J., Eleftheriou, C., Allen, A. E., Milosavljevic, N., Pienaar, A., Bedford, R., Davis, K. E., Bishop, P. N., & Lucas, R. J. (2015) · Current Biology · doi:10.1016/j.cub.2015.07.029 · Cited by 184
Zoltowski, B. D., & Gardner, K. H. (2010) · Biochemistry · doi:10.1021/bi101665s · Cited by 184
(2008) · PubMed Central · Cited by 183
Sengupta, A., Chaffiol, A., Macé, E., Caplette, R., Desrosiers, M., Lampič, M., Forster, V., Marre, O., Lin, J. Y., Sahel, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505699 · Cited by 180
Kotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169 · cited 2×
“One general concern for AAV vectors is that pre-existing immunity and subsequent induced adaptive immunity following vector administration can significantly reduce retinal gene expression, as shown in pre-clinical studies [82].”
BackgroundYiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153
Tomita, H., Sugano, E., Isago, H., Hiroi, T., Wang, Z., Ohta, E., & Tamai, M. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2009.12.006 · Cited by 148
The Retina: A Window into the Brain
Ptito, M., Bleau, M., & Bouskila, J. (2021) · Cells · doi:10.3390/cells10123269 · Cited by 148
Optogenetic Vision Restoration Using Rhodopsin for Enhanced Sensitivity
Gaub, B. M., Berry, M. H., Holt, A. E., Isacoff, E. Y., & Flannery, J. G. (2015) · Molecular Therapy · doi:10.1038/mt.2015.121 · Cited by 147
Sahel, J.-A., & Roska, B. (2013) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170304 · Cited by 140
Thyagarajan, S., van Wyk, M., Lehmann, K., Lowel, S., Feng, G., & Wassle, H. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4417-09.2010 · Cited by 139
Gauvain, G., Akolkar, H., Chaffiol, A., Arcizet, F., Khoei, M. A., Desrosiers, M., Jaillard, C., Caplette, R., Marre, O., Bertin, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01594-w · Cited by 129
Light damage to the retina: an historical approach
Norren, D. V., & Vos, J. J. (2015) · Eye · doi:10.1038/eye.2015.218 · Cited by 123
From channelrhodopsins to optogenetics
Hegemann, P., & Nagel, G. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202387 · Cited by 121
Rajala, A., Wang, Y., Zhu, Y., Ranjo-Bishop, M., Ma, J.-X., Mao, C., & Rajala, R. V. S. (2014) · Nano Letters · doi:10.1021/nl502275s · Cited by 117
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117
Ocular gene delivery using lentiviral vectors
Balaggan, K. S., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.153 · Cited by 113
Fischer, M. D., McClements, M. E., Martinez-Fernandez de la Camara, C., Bellingrath, J.-S., Dauletbekov, D., Ramsden, S. C., Hickey, D. G., Barnard, A. R., & MacLaren, R. E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.005 · Cited by 112 · cited 1×
“Common drawbacks that have plagued the usage of AAVs as vectors for gene delivery, including the ability to only transfect particular cell types and a size limitation of packaging capability, do not seem to limit the applicability of optogenetic approaches because optogenetic coding sequences are relatively small in c…”
BackgroundCai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109 · cited 2×
“ChR2, isolated from the green algae Chlamydomonas, is the most commonly used microbial opsin to date and maximally absorbs blue light at a wavelength of approximately 470 nm, which generates a depolarizing inward current in the cell [32].”
BackgroundOptogenetic approaches to vision restoration
Simunovic, M. P., Shen, W., Lin, J. Y., Protti, D. A., Lisowski, L., & Gillies, M. C. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2018.09.003 · Cited by 109
Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108 · cited 2×
“An advantage of subretinal injection is a more favorable biodistribution profile compared to intravitreal injection, thereby decreasing the risk of systemic exposure and inflammation [94].”
BackgroundDe Silva, S. R., Barnard, A. R., Hughes, S., Tam, S. K. E., Martin, C., Singh, M. S., Barnea-Cramer, A. O., McClements, M. E., During, M. J., Peirson, S. N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701589114 · Cited by 89
Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances
McClements, M. E., Staurenghi, F., MacLaren, R. E., & Cehajic-Kapetanovic, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.570909 · Cited by 69
Retinal Ganglion Cells are Resistant to Photoreceptor Loss in Retinal Degeneration
Lin, B., & Peng, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068084 · Cited by 65
Suprachoroidal gene transfer with nonviral nanoparticles
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A. (2020) · Science Advances · doi:10.1126/sciadv.aba1606 · Cited by 63 · cited 4×
“Further, biodegradable poly(β-amino ester) nanoparticle-based delivery of a plasmid encoding vascular endothelial growth factor (VEGF) neutralizing protein, p3sF1t1Fc, significantly suppressed vascular leakage and neovascularization in a mouse model of wet age-related macular degeneration (AMD) [36].”
BackgroundInfluentialGlycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2.
Cehajic‐Kapetanovic, J., Goff, M. L., Allen, A. E., Lucas, R. J., & Bishop, P. N. (2011) · PubMed Central · Cited by 57
Retinal transduction profiles by high-capacity viral vectors
Puppo, A., Cesi, G., Marrocco, E., Piccolo, P., Jacca, S., Shayakhmetov, D. M., Parks, R. J., Davidson, B. L., Colloca, S., Brunetti-Pierri, N., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.57 · Cited by 56
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Charbel Issa, P., De Silva, S. R., Lipinski, D. M., Singh, M. S., Mouravlev, A., You, Q., Barnard, A. R., Hankins, M. W., During, M. J., & MacLaren, R. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060361 · Cited by 53
Restoring vision in mice with retinal degeneration using multicharacteristic opsin
Wright, W. W., Gajjeraman, S., Batabyal, S., Pradhan, S., Bhattacharya, S., Mahapatra, V., Tripathy, A., & Mohanty, S. K. (2017) · Neurophotonics · doi:10.1117/1.nph.4.4.041505 · Cited by 48
Inhibition of cytochrome oxidase and blue-light damage in rat retina
Chen, E. (1993) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf00919652 · Cited by 44
Batabyal, S., Gajjeraman, S., Pradhan, S., Bhattacharya, S., Wright, W. W., & Mohanty, S. K. (2020) · Gene Therapy · doi:10.1038/s41434-020-00200-2 · Cited by 42
Han, Z., Koirala, A., Makkia, R., Cooper, M. J., & Naash, M. I. (2012) · Nanomedicine · doi:10.2217/nnm.11.158 · Cited by 41
Simon, C.-J., Sahel, J.-A., Duebel, J., Herlitze, S., & Dalkara, D. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.117 · Cited by 38
Tummala, G., Crain, A., Rowlan, J., & Pepple, K. L. (2021) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.62.2.41 · Cited by 36 · cited 1×
“Furthermore, there is growing appreciation for the risk of gene therapy associated uveitis following AAV administration, which appears to be related to the vector dose and route of administration [83,84].”
BackgroundTeo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24333 · Cited by 33
Prosseda, P. P., Alvarado, J. A., Wang, B., Kowal, T. J., Ning, K., Stamer, W. D., Hu, Y., & Sun, Y. (2020) · Science Advances · doi:10.1126/sciadv.aay8699 · Cited by 31
Self-citationCehajic-Kapetanovic, J., Milosavljevic, N., Bedford, R. A., Lucas, R. J., & Bishop, P. N. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.002 · Cited by 30 · cited 1×
“Intravitreal injection is a less technically challenging procedure and therefore less prone to complications [95,96].”
BackgroundNuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00287-1 · Cited by 29
Geeraerts, E., Claes, M., Dekeyster, E., Salinas‐Navarro, M., Groef, L. D., den Haute, C. V., Scheyltjens, I., Baekelandt, V., Arckens, L., & Moons, L. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0872-18.2018 · Cited by 26
Cell transplantation to replace retinal ganglion cells faces challenges – the Switchboard Dilemma
Lee, R., & Liu, Y. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.300329 · Cited by 22
Kowal, T. J., Prosseda, P. P., Ning, K., Wang, B., Alvarado, J. A., Sendayen, B. E., Jabbehdari, S., Stamer, W. D., Hu, Y., & Sun, Y. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.6.10 · Cited by 19
Self-citation
Research works printed but not linked: 1
- 79. Martel, J.N.; Boulanger-Scemama, E.; Degli Esposti, S.; Galluppi, F.; Blouin, L.; Taiel, M.; Sahel, J.A. Optogenetic GS030 Therapy in Subjects with Retinitis Pigmentosa: Safety and Tolerability Up to Two Years After Treatment Administration in the Phase 1/2a PIONEER Study. Investigative Ophthalmology & Visual Science 2021 , 62 , 3236.
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Gene Therapy for Inherited Retinal Diseases: From Laboratory Bench to Patient Bedside and Beyond
Brar, A. S., Parameswarappa, D. C., Takkar, B., Narayanan, R., Jalali, S., Mandal, S., Fujinami, K., & Padhy, S. K. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00862-2 · Cited by 49
Camouflage Nanoparticles Enable in Situ Bioluminescence-Driven Optogenetic Therapy of Retinoblastoma
Ding, J., Lu, J., Zhang, Q., Xu, Y., Song, B., Wu, Y., Shi, H., Chu, B., Wang, H., & He, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c00470 · Cited by 30
AAV genome modification for efficient AAV production
Asaad, W., Volos, P., Maksimov, D. O., Khavina, E. M., Deviatkin, A. A., Mityaeva, O. N., & Volchkov, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15071 · Cited by 33
Current approaches to vision restoration using optogenetic therapy
Parnami, K., & Bhattacharyya, A. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1236826 · Cited by 28
Metadata
- Authors
- Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y.
- Affiliations
- Stanford Medicine (US)
- University of Nevada, Reno (US)
- Corresponding author
- Sun, Yang
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2022-02-08
- Volume
- 12
- Issue
- 2
- Pages
- 269
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC8961521
- OpenAlex
- W4211263455
- Cited by
- 41
- References
- 99
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7 · 2023: 12 · 2022: 4
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NIH) / National Eye Institute (NEI) (K08-EY022058; R01-EY025295; F32-EY032775-01; T32-EY027816)
- U.S. Department of Veterans Affairs (CX001298)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Photoreceptor and optogenetics research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- optogenetics, vision restoration, retinal degeneration, glaucoma, retinitis pigmentosa, photoreceptor replacement, light-sensitive proteins, OCRL, intraocular pressure, trabecular meshwork, retinal dystrophy, gene therapy vectors, clinical trials
- MeSH terms
- Animals, Retina, Retinal Degeneration, Retinitis Pigmentosa, Vision, Ocular, Optogenetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
